Slim
Tirzepatide
Metabolic freedom, achieved.
Choose vial size
Order Inclusions
What it does for you
- /01Sends fullness signals to your brain so cravings quiet down naturally
- /02Works on two hunger pathways, not just one, for stronger results
- /03Helps your body handle sugar more smoothly, with fewer spikes and crashes
- /04Clinically shown to reduce body weight more than most single-target alternatives
Batch Documentation
Tirzepatide Research Notes
What is Tirzepatide?
Tirzepatide is a dual GLP-1 and GIP receptor agonist peptide studied for metabolic regulation, appetite control, and body composition. It was the first dual-agonist in this class to complete large-scale clinical trials, making it the most comprehensively documented peptide in the incretin category after semaglutide.
GLP-1 activation suppresses appetite and slows gastric emptying. GIP activation enhances insulin sensitivity and supports fat metabolism. Together they produce complementary metabolic effects not achievable with GLP-1 agonism alone. The SURMOUNT-1 trial demonstrated mean weight reductions of up to 22.5% over 72 weeks at the highest studied dose.
Not approved for general medical use in Indonesia. Available here strictly as a research compound.
What the research shows
SURMOUNT-1 trial: 2,539 participants over 72 weeks. Mean weight loss up to 22.5% at 15mg. Improvements in waist circumference, blood pressure, fasting glucose, and lipid profiles recorded.
GIP co-activation: Appears to improve tolerability relative to GLP-1-only compounds.
Side effects: Nausea, diarrhea, reduced appetite — mild to moderate, dose-dependent, most pronounced during titration.
Reference: Jastreboff A.M. et al. (2022). NEJM, 387(3), 205–216.
Ordering Tirzepatide in Bali
Not classified as a controlled substance under Indonesian BPOM regulations. Same-day delivery may be possible only after the team confirms the exact item, current availability, route, daily cutoff, complete villa or hotel address, and timing before ordering.
Common Questions
Q: How does it differ from semaglutide?
Semaglutide is GLP-1 only. Tirzepatide adds GIP receptor activation. Trial data generally shows greater weight reduction with tirzepatide.
Q: How does it compare to retatrutide?
Retatrutide adds glucagon receptor activation on top. Phase II data suggests greater weight reduction with retatrutide but tirzepatide has a larger clinical data record.
Q: Starting dose?
Research protocols generally begin low and titrate every 4 weeks to manage GI side effects.
Q: Storage?
Refrigerate at 2–8°C. Use within 28 days of reconstitution. Ships cold-packed.
Research by goal
Explore Tirzepatide in context
Read the relevant goal guides to understand the research area, adjacent compounds, and the questions each track explores.